161 related articles for article (PubMed ID: 9167034)
1. Budesonide in the management of patients with Crohn's disease.
Thomson AB; Sadowski D; Jenkins R; Wild G
Can J Gastroenterol; 1997 Apr; 11(3):255-60. PubMed ID: 9167034
[TBL] [Abstract][Full Text] [Related]
2. Controlled-release budesonide in Crohn's disease.
Drug Ther Bull; 1997 Apr; 35(4):30-1. PubMed ID: 9282408
[TBL] [Abstract][Full Text] [Related]
3. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
[TBL] [Abstract][Full Text] [Related]
4. Budesonide for induction of remission in Crohn's disease.
Otley A; Steinhart AH
Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
[TBL] [Abstract][Full Text] [Related]
5. A comparison of budesonide with prednisolone for active Crohn's disease.
Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
[TBL] [Abstract][Full Text] [Related]
6. Treatment of joint pain in Crohn's patients with budesonide controlled ileal release.
Florin TH; Graffner H; Nilsson LG; Persson T
Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):295-8. PubMed ID: 10779128
[TBL] [Abstract][Full Text] [Related]
7. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
McKeage K; Goa KL
Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
[TBL] [Abstract][Full Text] [Related]
8. Budesonide in inflammatory bowel disease.
Lamers CB; Wagtmans MJ; van der Sluys Veer A; van Hogezand RA; Griffioen G
Neth J Med; 1996 Feb; 48(2):60-3. PubMed ID: 8819801
[TBL] [Abstract][Full Text] [Related]
9. Budesonide or prednisolone in active Crohn's disease.
Baert F; Rutgeerts P
Ann Med; 1995 Dec; 27(6):631. PubMed ID: 8652141
[No Abstract] [Full Text] [Related]
10. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
[TBL] [Abstract][Full Text] [Related]
11. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
12. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
[TBL] [Abstract][Full Text] [Related]
13. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
15. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
Escher JC;
Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):47-54. PubMed ID: 15095852
[TBL] [Abstract][Full Text] [Related]
16. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
Gastroenterology; 1996 Jan; 110(1):45-51. PubMed ID: 8536887
[TBL] [Abstract][Full Text] [Related]
17. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.
Spencer CM; McTavish D
Drugs; 1995 Nov; 50(5):854-72. PubMed ID: 8586030
[TBL] [Abstract][Full Text] [Related]
18. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.
Gross V; Andus T; Ecker KW; Raedler A; Loeschke K; Plauth M; Rasenack J; Weber A; Gierend M; Ewe K; Schölmerich J
Gut; 1998 Apr; 42(4):493-6. PubMed ID: 9616309
[TBL] [Abstract][Full Text] [Related]
19. Budesonide for maintenance of remission in Crohn's disease.
Simms L; Steinhart AH
Cochrane Database Syst Rev; 2001; (1):CD002913. PubMed ID: 11279777
[TBL] [Abstract][Full Text] [Related]
20. Budesonide for induction of remission in Crohn's disease.
Seow CH; Benchimol EI; Griffiths AM; Otley AR; Steinhart AH
Cochrane Database Syst Rev; 2008 Jul; (3):CD000296. PubMed ID: 18646064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
